Stock comparison
Boston Scientific
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BSX
Boston Scientific
Market cap
$85.88B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BSX | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 79B | HALO |
| Benjamin Graham | 69B | 83A | HALO |
| Philip Fisher |
Side-by-side metrics
| Metric | BSX | HALO |
|---|---|---|
| Market cap | $85.88B | $8.1B |
| P/E (TTM) | 22.0x | 24.0x |
| EV/EBIT | 22.1x | 10.2x |
| ROIC (TTM) | 9.9% | 23.65% |
| Gross margin | 70.41% | 81.24% |
| Net margin | 17.24% | 23.13% |
| Revenue CAGR 5y | 13.99% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BSX leads on
- EPS CAGR 5y29.71%vs -1.98%+107%
- Market cap$85.88Bvs $8.1B+91%
- Debt / Equity0.4xvs 1.0x+55%
- P/E (TTM)22.0xvs 24.0x
More like HALO
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.